Your browser doesn't support javascript.
loading
Using Workflow Modeling to Identify Areas to Improve Genetic Test Processes in the University of Maryland Translational Pharmacogenomics Project.
Cutting, Elizabeth M; Overby, Casey L; Banchero, Meghan; Pollin, Toni; Kelemen, Mark; Shuldiner, Alan R; Beitelshees, Amber L.
Afiliação
  • Cutting EM; Program in Personalized and Genomic Medicine and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Overby CL; Program in Personalized and Genomic Medicine and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Banchero M; Program in Personalized and Genomic Medicine and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Pollin T; Program in Personalized and Genomic Medicine and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Kelemen M; Program in Personalized and Genomic Medicine and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Shuldiner AR; Program in Personalized and Genomic Medicine and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Beitelshees AL; Program in Personalized and Genomic Medicine and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
AMIA Annu Symp Proc ; 2015: 466-74, 2015.
Article em En | MEDLINE | ID: mdl-26958179
Delivering genetic test results to clinicians is a complex process. It involves many actors and multiple steps, requiring all of these to work together in order to create an optimal course of treatment for the patient. We used information gained from focus groups in order to illustrate the current process of delivering genetic test results to clinicians. We propose a business process model and notation (BPMN) representation of this process for a Translational Pharmacogenomics Project being implemented at the University of Maryland Medical Center, so that personalized medicine program implementers can identify areas to improve genetic testing processes. We found that the current process could be improved to reduce input errors, better inform and notify clinicians about the implications of certain genetic tests, and make results more easily understood. We demonstrate our use of BPMN to improve this important clinical process for CYP2C19 genetic testing in patients undergoing invasive treatment of coronary heart disease.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacogenética / Testes Genéticos / Centros Médicos Acadêmicos / Medicina de Precisão / Fluxo de Trabalho Tipo de estudo: Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Revista: AMIA Annu Symp Proc Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacogenética / Testes Genéticos / Centros Médicos Acadêmicos / Medicina de Precisão / Fluxo de Trabalho Tipo de estudo: Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Revista: AMIA Annu Symp Proc Ano de publicação: 2015 Tipo de documento: Article